Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
Eloy E. Ordaya, Elena Beam, Joseph D. Yao, Raymund R. Razonable, Paschalis Vergidis
Abstract
Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakRespiratory systemIntensive care medicineTransmission (telecommunications)PediatricsImmunologyVirologyDiseaseInternal medicineInfectious disease (medical specialty)OutbreakEngineeringElectrical engineeringCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impacts